Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...

Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., ...

GSK has been the dominant player in the RSV vaccine market since Arexvy first gained approval in 2023, although Pfizer has made inroads into its market share. While initial launches for both ...

Dormitzer also took the lead on Pfizer's respiratory syncytial virus (RSV) vaccine candidates ... now started testing, while GSK has also focused on providing its adjuvant technology to other ...

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Earlier this month ...

China is yet to approve a RSV vaccine, unlike the U.S. which has given the green light to shots from GSK, Moderna and Pfizer, but multiple candidates have reached the clinic ahead of Ab&B.

“Should we have an RSV vaccine for older Australians? Absolutely. We have two highly effective vaccines, one made by GSK, one made by Pfizer, which are being implemented and used widely now in ...

Respiratory syncytial virus (RSV) is a leading ... and pregnant women. GlaxoSmithKline is evaluating a prefusion F protein vaccine in adults with an undisclosed adjuvant(s). MedImmune is assessing ...

Despite 50 years of research, there are currently no RSV vaccines ... pregnant women. GlaxoSmithKline is evaluating a prefusion F protein vaccine in adults with an undisclosed adjuvant(s).